US FDA Manufacturing Inspections: What Indian Pharma Companies Can Learn

One inspection can reveal what months of internal reviews may miss.

For an Indian pharmaceutical manufacturer, a US FDA inspection is not simply a regulatory visit. It is an opportunity for an investigator to look closely at how the company actually operates, from manufacturing and laboratory controls to documentation, data integrity, validation, investigations, and quality oversight.

And the lesson is becoming increasingly relevant for Indian pharma.

In 2026, the FDA issued warning letters to several pharmaceutical facilities in India. For example, inspections involving Dabur India Limited, Shimoga Chemicals, Auriga Research Pvt. Ltd., and Reliance Life Sciences resulted in regulatory findings involving areas such as quality-unit responsibilities, CGMP controls, investigations, data, and manufacturing practices.

These cases should not be treated as a checklist of what every Indian manufacturer is doing wrong. Instead, they provide a useful reminder of what can attract regulatory attention.

So, what can Indian pharmaceutical companies learn from US FDA manufacturing inspections?

The answer begins with a simple principle: inspection readiness should be built into everyday manufacturing, not created a few weeks before an inspector arrives.

Let's look at what an FDA inspection involves and the practical lessons Indian pharma companies can take from it.

What Can Indian Pharma Companies Learn From US FDA Inspections?

US FDA manufacturing inspections show Indian pharma companies where compliance systems can become vulnerable. The key lessons are to maintain strong GMP compliance, protect data integrity, keep complete manufacturing records, strengthen CAPA and root-cause investigations, validate critical processes, and ensure employees are always inspection-ready.

What Is a US FDA Manufacturing Inspection?

A US FDA manufacturing inspection is an examination of a pharmaceutical facility, its operations, records, systems, and controls to assess compliance with applicable regulatory requirements.

For drug manufacturers, FDA inspections can cover areas such as manufacturing processes, quality control, laboratory operations, equipment, documentation, validation, complaints, investigations, and quality-unit responsibilities.

The inspection is therefore much broader than simply checking whether products are manufactured according to a written procedure.

Read also: CDMO vs Third-Party Manufacturing: A Practical Pharma Comparison

What Can FDA Investigators Examine?

Depending on the facility and inspection objectives, investigators may review:

• Manufacturing and process controls

• Batch production records

• Standard operating procedures

• Laboratory testing

• Quality control and quality assurance

• Equipment maintenance

• Cleaning and contamination controls

• Process validation

• Deviation investigations

• CAPA (Corrective and Preventive Action)

• Employee training

• Electronic and paper records

• Data integrity

• Supplier and contractor controls

This is why pharma manufacturing readiness should be treated as an ongoing responsibility rather than an activity that begins when an inspection notice arrives.

Why FDA Inspection Readiness Matters for Indian Pharma Companies

India has a large and increasingly global pharmaceutical manufacturing sector. Many manufacturers supply products to highly regulated international markets, making regulatory readiness an important part of long-term growth.

For a company targeting the US, compliance cannot be separated from commercial strategy.

A manufacturing problem can potentially affect:

• Product supply

• Customer confidence

• Regulatory relationships

• Market access

• Export timelines

• Manufacturing costs

• Business reputation

This makes pharmaceutical export compliance a business priority as well as a regulatory one.

Indian manufacturers should therefore ask a simple question:

“If an FDA investigator arrived tomorrow, could we demonstrate that our systems are working, not just that our SOPs exist?”

That question captures the difference between having documentation and having a genuinely effective quality system.

7 Areas Indian Pharma Companies Should Strengthen Before an FDA Inspection

1. Good Manufacturing Practices

At the foundation of pharmaceutical compliance are Good Manufacturing Practices (GMP).

GMP controls help ensure that medicines are consistently produced and controlled according to appropriate quality standards.

Indian manufacturers should routinely review whether their manufacturing processes, documentation, personnel practices, facilities, equipment, and quality systems are operating as intended.

GMP should not be viewed as an inspection-day requirement. It should be part of the company's daily manufacturing culture.

2. Documentation and Recordkeeping

In pharmaceutical manufacturing, undocumented work can be difficult to demonstrate.

FDA investigators may examine records to determine whether actual manufacturing activities match approved procedures.

Companies should therefore pay close attention to:

• Batch manufacturing records

• SOPs

• Laboratory records

• Equipment logs

• Cleaning records

• Deviation reports

• Change-control documents

• Investigation reports

• Training records

Good documentation should be accurate, complete, traceable, and created at the appropriate time.

A useful internal question is:

Can another qualified person reconstruct what happened simply by reviewing the records?

If the answer is no, the documentation system deserves attention.

3. Data Integrity

FDA data integrity has become one of the most important areas of pharmaceutical quality management.

Whether information is recorded on paper or electronically, manufacturers need controls that protect its reliability and traceability.

Important areas include:

• Audit trails

• User access controls

• Electronic records

• Laboratory data

• Original records

• Data review

• Backup procedures

• Record retention

Data integrity should involve more than the IT department. Production, quality assurance, quality control, laboratories, engineering, and management all have roles to play.

A strong system should allow the company to demonstrate that its records accurately reflect the activities performed.

4. Validation and Manufacturing Controls

A pharmaceutical process should not simply appear to work; it should be appropriately demonstrated to operate consistently.

That makes process validation, equipment qualification, cleaning validation, and other manufacturing controls important components of inspection readiness.

Manufacturers should periodically assess:

• Whether validation remains current

• Whether processes remain controlled

• Whether equipment is properly maintained

• Whether cleaning procedures remain effective

• Whether changes have been appropriately evaluated

• Whether recurring deviations indicate an underlying process weakness

Validation should be treated as an ongoing quality activity rather than a one-time documentation exercise.

5. CAPA and Root-Cause Analysis

A recurring mistake in quality management is treating the symptom rather than the cause.

For example, if a manufacturing deviation occurs, correcting the immediate problem may not prevent it from happening again.

This is where FDA CAPA requirements, investigation systems, and root cause analysis become important.

An effective CAPA system should answer:

1. What happened?

2. Why did it happen?

3. What is the actual root cause?

4. Could the same problem exist elsewhere?

5. What corrective action is required?

6. How will effectiveness be verified?

A CAPA that simply closes paperwork without addressing the underlying risk is unlikely to provide lasting value.

6. Quality Unit Oversight

Quality assurance and quality control functions play an important role in maintaining pharmaceutical quality.

Companies should ensure that responsibilities are clearly defined and that quality personnel have appropriate authority and independence.

The quality unit should not merely approve documents. It should actively participate in investigations, deviations, CAPA, change control, validation oversight, and other quality decisions.

Strong pharmaceutical quality systems create a structure where quality issues are identified and addressed before they become larger compliance problems.

7. Employee Training

An SOP cannot protect a product if employees do not understand how to follow it.

Employees involved in manufacturing, testing, quality, engineering, warehousing, and other regulated activities should receive appropriate training for their responsibilities.

More importantly, training should be meaningful.

Employees should understand:

• What their procedure requires

• Why the procedure matters

• What records they need to create

• When to report a deviation

• How to protect data

• Who to contact when something goes wrong

During an inspection, employees should be able to explain their responsibilities clearly and honestly.

FDA Form 483: What Indian Manufacturers Should Know

One of the most commonly discussed terms following an FDA inspection is FDA Form 483.

Form FDA 483 is used by investigators to communicate inspectional observations when they identify conditions that may represent violations of applicable requirements.

However, Form 483 should not automatically be described as a final FDA enforcement decision. FDA explains that the form contains observations made during an inspection, while the agency's subsequent compliance review considers additional information and the company's response.

What Should a Company Do After Receiving Form 483?

The response should be structured, factual, and supported by evidence.

A company should carefully evaluate:

• The observation

• The underlying root cause

• Immediate corrections

• Corrective actions

• Preventive actions

• Supporting documentation

• Implementation timelines

• Effectiveness checks

The objective should not simply be to “answer FDA.”

The objective should be to demonstrate that the organization understands the underlying quality risk and has established sustainable controls.

FDA Warning Letters: Another Important Lesson

A warning letter represents a different stage of FDA regulatory communication.

For Indian pharmaceutical manufacturers, FDA warning letters can provide useful insight into the types of compliance weaknesses regulators consider significant.

Recent FDA enforcement records involving Indian facilities have included concerns relating to areas such as quality systems, manufacturing controls, validation, documentation, and data integrity.

This is why companies should not wait until they receive an observation to begin corrective action.

Read also: Pharmaceutical Exports to the US: Understanding New Tariff Rules

The better strategy is prevention.

Manufacturers can review publicly available FDA enforcement information and use recurring themes as prompts for internal risk assessments.

Schedule M Compliance and FDA Readiness

Schedule M compliance is highly relevant to Indian pharmaceutical manufacturing because it establishes requirements concerning manufacturing practices and quality systems in India.

However, companies should avoid treating Schedule M and US FDA requirements as interchangeable.

A manufacturer supplying the US market must understand and meet the requirements applicable to that market, while also maintaining compliance with Indian regulations.

This makes regulatory mapping important.

A company can use its Schedule M compliance program as part of its broader quality foundation while separately evaluating US-specific expectations.

Learn more about Schedule M Compliance for Pharma Manufacturers in India.

FDA Inspection Readiness Checklist

Before an FDA inspection or before entering a regulated export market, Indian manufacturers can review the following:

Area	Questions to Ask
GMP	Are manufacturing processes consistently controlled?
Documentation	Are records complete, accurate, and traceable?
Data Integrity	Are electronic and paper records properly controlled?
CAPA	Are root causes properly identified and addressed?
Validation	Are critical processes appropriately validated?
Equipment	Are maintenance and qualification records current?
Cleaning	Are cleaning procedures and validation adequately controlled?
Laboratory	Are testing procedures and records reliable?
Training	Can employees explain their responsibilities?
Quality Unit	Are QA/QC responsibilities clearly defined?
Suppliers	Are critical suppliers appropriately qualified and monitored?
Export	Are destination-specific pharma export requirements understood?

This checklist can become a useful internal starting point for a broader inspection-readiness program.

What About Third-Party Pharmaceutical Manufacturing?

Not every pharmaceutical company owns and operates its manufacturing facility.

Many businesses rely on third-party pharmaceutical manufacturing partners for production, packaging, or other manufacturing requirements.

In such cases, outsourcing manufacturing does not mean outsourcing the need for due diligence.

Before selecting a manufacturing partner, companies should evaluate:

• Manufacturing capabilities

• Quality systems

• GMP practices

• Documentation

• Testing facilities

• Validation systems

• Certifications

• Regulatory experience

• Product-specific capabilities

• Ability to support target export markets

For companies evaluating international supply opportunities, WHO-GMP certified pharmaceutical manufacturing may be an important consideration, depending on the product, customer, and destination-market requirements.

Businesses looking for manufacturing support can explore Monark Biocare's third-party pharmaceutical manufacturing solutions.

Pharmaceutical Export Compliance: Think Beyond the Factory

A manufacturer can produce a quality medicine and still face challenges when entering an international market.

Why?

Because pharmaceutical export compliance extends beyond manufacturing.

Depending on the destination, companies may need to consider:

• Product registration

• Market authorization

• Labeling

• Packaging

• Testing

• Certificates

• Import requirements

• Regulatory documentation

• Customer-specific specifications

• Pharmacovigilance obligations

This is particularly important for companies exploring new pharmaceutical export markets.

Manufacturers involved in api manufacturing in India, finished-dose manufacturing, or contract manufacturing should identify the regulatory expectations of the destination market before making major commercial commitments.

In other words:

Export planning should begin before production, not after it.

Key Lessons Indian Pharma Companies Can Take From FDA Inspections

The most valuable lessons can be summarized in five points:

➜ Build Quality Into Everyday Operations

Inspection readiness begins with routine compliance, not last-minute preparation.

➜ Treat Data as a Quality Asset

Reliable records are essential for demonstrating control over manufacturing and testing.

➜ Investigate Problems Properly

A strong root-cause investigation is more valuable than a quick correction that only addresses the symptom.

➜ Keep Documentation Inspection-Ready

If a process matters, the records supporting that process matter too.

➜ Think Globally About Compliance

Indian regulatory compliance is essential, but companies targeting international markets must also understand destination-specific requirements.

US FDA Pharmaceutical Inspection & Compliance

The U.S. Food and Drug Administration (FDA) regularly conducts inspections of pharmaceutical manufacturing facilities to evaluate compliance with Current Good Manufacturing Practice (CGMP) requirements. These inspections can review manufacturing operations, quality systems, laboratory controls, documentation, data integrity, and corrective actions.

According to the FDA, inspection findings may be documented through Form FDA 483, which identifies observations made by investigators at the conclusion of an inspection. FDA inspection outcomes can be classified as NAI (No Action Indicated), VAI (Voluntary Action Indicated), or OAI (Official Action Indicated).

For Indian pharmaceutical manufacturers, FDA inspection records and warning letters provide useful real-world examples of compliance weaknesses that can affect facilities supplying the U.S. market. Recent FDA actions involving Indian facilities have highlighted areas such as quality-unit responsibilities, manufacturing controls, investigations, CAPA, documentation, and CGMP compliance.

Official Data Source:
U.S. FDA – Pharmaceutical Inspections and Compliance

Final Takeaway

A successful FDA inspection is rarely the result of a few weeks of preparation.

It is usually the result of months and years of consistent quality practices.

For Indian pharmaceutical manufacturers, that means strengthening Good Manufacturing Practices (GMP), maintaining Schedule M compliance, protecting data integrity, managing CAPA effectively, validating processes, training employees, and keeping documentation ready for review.

It also means understanding that pharmaceutical export compliance is broader than manufacturing alone.

Whether a company manufactures in-house or works with a third-party pharmaceutical manufacturing partner, the objective should remain the same: build reliable systems that can withstand regulatory scrutiny and support sustainable access to international markets.

For manufacturers and businesses seeking pharmaceutical manufacturing solutions, Monark Biocare can be explored as a potential manufacturing partner based on the specific product and market requirements.

Contact Information

Monark Biocare

Location: Plot No. 201, HSIIDC, Alipur, Barwala, Haryana, India

Email: monarkbiocare@gmail.com

Phone:

• +91-9855986633

• +91-9023256719

• +91-9888656719

Disclaimer: Regulatory requirements may vary according to the product, facility, regulatory pathway, and destination market. Manufacturers should verify current requirements with the relevant regulatory authorities and qualified regulatory professionals before making compliance or export decisions.

Frequently Asked Questions

What does the FDA check during a pharmaceutical manufacturing inspection?

FDA investigators may review manufacturing processes, quality systems, laboratory controls, records, equipment, validation, documentation, personnel practices, and other areas relevant to applicable regulatory requirements.

What is FDA Form 483?

FDA Form 483 communicates inspectional observations identified by investigators when conditions may represent violations of applicable requirements. It is not itself a final agency determination of a violation.

How can Indian pharma companies prepare for an FDA inspection?

Companies can strengthen FDA inspection readiness through internal audits, employee training, documentation review, data-integrity controls, CAPA management, validation, deviation investigations, and mock inspections.

What are common FDA inspection observations?

Common areas of regulatory concern can include documentation, data integrity, manufacturing controls, validation, laboratory controls, quality-unit oversight, investigations, and CAPA.

Why is data integrity important for pharmaceutical manufacturers?

Data integrity helps ensure that records accurately represent manufacturing and testing activities. Reliable records support quality decisions and demonstrate control during regulatory review.

What is the difference between Form 483 and a warning letter?

Form 483 communicates inspectional observations. A warning letter is a subsequent regulatory communication concerning significant violations or concerns identified by FDA.

What should Indian manufacturers check before exporting medicines?

They should evaluate applicable pharma export requirements, product registration, documentation, labeling, testing, manufacturing controls, and the regulatory requirements of the destination country.